OncoBone Ventures has nominated Andrew King as non-executive director. At the same time, the CEO Jussi Halleen was nominated as the Chairman.
Andrew King has worked at a senior level in the financial world for over 30 years and has served as Chief Financial Officer to a number of AIM quoted and private companies in the biotech and medtech sectors. His experience in these industries stretches from start-ups through IPOs and includes trade sales to Big Pharma.
Jussi Halleen comments: “Having Andy on Board was an important strategic decision for OncoBone Ventures, and his experience as CFO and in trade sales and IPOs will be important for reaching our goals.”
